Industry
Biotechnology Validation
Biologics manufacturing brings living systems, complex downstream trains and increasingly modular facilities. Validation strategy has to accommodate single-use technology, rapid capacity changes and multi-product suites.
Upstream and downstream systems
- Bioreactors, media and buffer preparation, and hold systems
- Single-use assemblies, integrity testing and supplier qualification
- Chromatography skids, column packing and resin lifetime studies
- Tangential flow filtration and viral filtration systems
- Viral inactivation and clearance interfaces
- Fill-finish, freeze-thaw and cold chain equipment
Cell and gene therapy considerations
Autologous and small-batch processes compress schedules and reduce the tolerance for equipment downtime. Qualification and change control practices need to support frequent process evolution without losing the thread of what was validated, when, and for which product.
Multi-product suites and segregation
Shared facilities require an explicit contamination control and changeover strategy, supported by cleaning validation, environmental controls, and computerized systems that enforce segregation in scheduling, batch records and materials management.
Primary references
- FDA — Process Validation: General Principles and Practices
- FDA — Computer Software Assurance for Production and Quality System Software
- FDA — 21 CFR Part 11, Electronic Records; Electronic Signatures
- FDA — Data Integrity and Compliance With Drug CGMP
- FDA — General Principles of Software Validation
Information published on ValidationEngineering.com is educational and informational. It is not legal or regulatory advice and is not a guarantee of regulatory compliance or of any inspection outcome. Organizations remain responsible for their own quality decisions.
Next step
Validating a bioprocess facility or platform?
Tell us about the modality, scale and program stage.